Table 2.

Effects of Product Characteristics on Symptom Relief.

Outcome = Symptom Change (Ending - Starting Symptom)
	(1)	(2)	(3)	(4)	(5)
Panel A: Product Type, omitted category = flower
Concentrate	0.194**				0.080
	(0.076)				(0.212)
Edible	0.340***
	(0.105)
Tincture	0.498***
	(0.117)
Topical	−0.216
	(0.355)
Panel B: Subspecies, omitted category = hybrid
C. indica		−0.103**			−0.057
		(0.041)			(0.083)
C. sativa		0.096*			0.195
		(0.055)			(0.121)
Panel C: Combustion Method, omitted category = joint
Pipe			−0.061		−0.004
			(0.084)		(0.194)
Vape			0.051		0.051
			(0.092)		(0.210)
Panel D: THC and CBD, omitted categories = THC < 10% and CBD < 1%
THC 10–19%				−0.215*	−0.220*
				(0.117)	(0.134)
THC 20–34%				−0.235**	−0.315***
				(0.112)	(0.121)
THC 35%+				−0.252**	−0.342**
				(0.126)	(0.166)
CBD 1–9%				−0.089	−0.026
				(0.121)	(0.126)
CBD 10–34%				0.038	0.079
				(0.105)	(0.092)
CBD 35%+				−0.222	−0.241
				(0.209)	(0.227)
Starting Symptom Level	−0.704***	−0.721***	−0.726***	−0.709***	−0.717***
	(0.028)	(0.031)	(0.032)	(0.056)	(0.063)
Constant	0.588***	0.691***	0.719***	0.909***	0.850**
	(0.165)	(0.184)	(0.212)	(0.340)	(0.403)
Number of sessions	19,910	17,197	16,898	4,439	3,869
R-squared	0.330	0.340	0.338	0.337	0.346
Number of users	3,341	2,996	2,936	900	787

Notes: Regressions control for individual user fixed effects. Concentrate is relative to Flower, C. indica and C. sativa are relative to Hybrid, THC categories are relative to THC 0–9%, CBD categories are relative to CBD 0%, and Pipe and Vape are relative to Joint. Standard errors are clustered at the user level (shown in parentheses). ***p < 0.01, **p < 0.05, *p < 0.1.